New Delhi: India’s drug regulator has approved Itolizumab, a drug used to cure skin ailment psoriasis, for “restricted emergency use” to treat COVID-19 patients with moderate to severe acute respiratory distress.
Considering the unmet medical needs to treat COVID-19, Drugs Controller General of India, Dr VG Somani, approved the monoclonal antibody injection Itolizumab, on Friday, officials said.
“The approval was given after its clinical trials on COVID-19 patients in India were found satisfactory by an expert committee comprising pulmonologists, pharmacologists and medicine specialists from AIIMS, among others, for treatment of cytokine release syndrome,” PTI quoted an unnamed official as saying.
“It is already an approved drug of Biocon for treating psoriasis for last many years,” the official added.
He also informed that written informed consent of each patient is required before the use of this drug.
Koraput/Nabarangpur: Mounting a scathing attack on Odisha’s Biju Janata Dal (BJD) government, BJP leader and…
Mumbai: When ‘Sarfarosh’ hit theatres on April 1999, not many would have seen it emerging…
London: Leading climate activist Greta Thunberg was on Wednesday fined by a Stockholm court for…
Bhubaneswar: With rival political parties trading charges ahead of the twin elections in Odisha, senior…
Pune: All stakeholders have been feeling the heat since AstraZeneca admitted in UK court documents that…
Bhubaneswar: Heat slowly returned to western Odisha on Wednesday after a brief lull, while the…
New Delhi: Sam Pitroda has resigned as Chairman of Indian Overseas Congress in the wake…
Bhubaneswar: Thunderstorm coupled with rain and lightning is likely to hit at least nine districts…